TAG-72 Expression in Primary, Metastatic and Hormonally Treated Prostate Cancer as Defined by Monoclonal Antibody CC49

No AccessJournal of UrologyClinical Urology: Original Article1 May 1995TAG-72 Expression in Primary, Metastatic and Hormonally Treated Prostate Cancer as Defined by Monoclonal Antibody CC49 Phillip C. Brenner, Wolfgang J. Rettig, Pilar M. Sanz-Moncasi, Victor Reuter, Armen Aprikian, Lloyd J. Old, William R. Fair, and Pilar Garin-Chesa Phillip C. BrennerPhillip C. Brenner More articles by this author , Wolfgang J. RettigWolfgang J. Rettig More articles by this author , Pilar M. Sanz-MoncasiPilar M. Sanz-Moncasi More articles by this author , Victor ReuterVictor Reuter More articles by this author , Armen AprikianArmen Aprikian More articles by this author , Lloyd J. OldLloyd J. Old More articles by this author , William R. FairWilliam R. Fair More articles by this author , and Pilar Garin-ChesaPilar Garin-Chesa More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67465-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Monoclonal antibodies CC49 and B72.3, which recognize a tumor associated glycoprotein (TAG-72) related to sialyted Tn antigen, have been used in clinical trials for radionuclide imaging, and treatment of colon, breast and ovarian carcinoma. In addition, studies with CC49 in patients with metastatic hormone refractory prostate cancer have been initiated based on the observed expression of TAG-72 in primary prostate cancer. We examined whether TAG-72 expression is a common feature of primary, metastatic and hormonally treated prostatic carcinoma. Immunohistochemical analysis of 25 primary prostatic carcinomas confirmed previous data that 21 of 25 specimens (80 percent) were immunoreactive with CC49. CC49 staining was noted in all 6 well (Gleason score 2 to 4), 8 of 10 moderately (Gleason score 5 to 6) and 7 of 9 poorly (Gleason score 7 to 9) differentiated tumors. CC49 immunoreactivity was noted in 10 of 20 hormonally treated prostate cancers and in 21 of 25 tumors without hormonal therapy. Intense CC49 staining of prostatic intraepithelial neoplasia was present in all 5 specimens examined. In contrast to the primary lesion, many metastatic prostate cancers lacked detectable CC49 immunoreactivity. Of 24 pelvic lymph node metastases from different patients only 4 (17 percent) had significant CC49 staining and 5 others had rare CC49 positive cells. However, 6 of 12 bone metastases showed CC49 immune staining. One specimen from an anaplastic locally recurrent tumor showed no reactivity. To our knowledge we present the first analysis of TAG-72 expression in a large series of patients with hormonally treated and metastatic prostate cancer, the most likely candidates for CC49 immunotherapy. Our findings that lymph node and bone metastases from prostate cancer are less likely to express significant amounts of TAG-72 than primary prostate cancer suggest that pretreatment biopsy typing for TAG-72 may be necessary to optimize the results of ongoing CC49 imaging and therapy studies. References 1 : Radioimmunoscintography of prostate cancer.. Sem. Nucl. Med.1989; 19: 309. Google Scholar 2 : Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer.. Sem. Urol.1992; 10: 45. Google Scholar 3 : Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.. Cancer Res.1986; 46: 3118. Google Scholar 4 : Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.. Cancer Res.1988; 48: 4588. Google Scholar 5 : Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients.. Cancer Res.1993; 53: 271. Google Scholar 6 : Prostatic adenocarcinoma: evaluation of immunoreactivity to monoclonal antibody B72.3.. Amer. J. Clin. Path.1990; 93: 466. Google Scholar 7 : Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.. Cancer Res.1990; 50: 1291. Google Scholar 8 : Phase II trial of sup 131 I-labelled high affinity anti-TAG 72 antibody for metastatic prostate cancer. Antibody, Immunoconj. Radiopharmaceut.1993; 6: 89. Google Scholar 9 : Radioimmunoguided radical prostatectomy and lymphadenectomy.. Cancer1993; 71: 2268. Google Scholar 10 : Immunohistochemical analysis of human neuronectin expression in normal, reactive, and neoplastic tissues.. J. Histochem. Cytochem.1989; 37: 1767. Google Scholar 11 Armas, A. A., Aprikian, A. G., Melamed, J., Cordon-Cardo, C., Cohen, D. W., Erlandson, R., Fair, W. R. and Reuter, V. E.: Clinical and pathobiological effects of neoadjuvant total androgen ablation on clinically localised prostatic adenocarcinoma. Amer. J. Surg. Path., in press. Google Scholar 12 : A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.. Int. J. Cancer1982; 29: 539. Google Scholar 13 : Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas.. Int. J. Cancer1983; 31: 543. Google Scholar 14 : A tumor-associated antigen in carcinoma of the pancreas defined by monoclonal antibody B72.3.. Amer. J. Clin. Path.1988; 89: 160. Google Scholar 15 : Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas.. Int. J. Cancer1987; 40: 726. Google Scholar 16 : Phenotypic heterogeneity of a tumor-associated antigen in adenocarcinomas of the colon and their metastases as demonstrated by monoclonal antibody B72.3.. Cancer Invest.1986; 4: 387. Google Scholar 17 : Regional heterogeneity and complementation in the expression of the tumor-associated glycoprotein 72 epitopes in colorectal cancer.. Cancer Res.1991; 51: 5378. Google Scholar 18 : Heterogeneity of antigen expression in advanced epithelial ovarian cancer.. Amer. J. Obst. Gynec.1990; 162: 883. Google Scholar 19 : Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Res.. Treat.1985; 6: 49. Google Scholar From the Urology Service, Departments of Surgery and Pathology, Memorial Sloan-Kettering Cancer Center, Immunology Program, Sloan Kettering Institute and Ludwig Institute for Cancer Research, New York, New York.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 153Issue 5May 1995Page: 1575-1579 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Phillip C. Brenner More articles by this author Wolfgang J. Rettig More articles by this author Pilar M. Sanz-Moncasi More articles by this author Victor Reuter More articles by this author Armen Aprikian More articles by this author Lloyd J. Old More articles by this author William R. Fair More articles by this author Pilar Garin-Chesa More articles by this author Expand All Advertisement PDF downloadLoading ...